Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Steroid vs. Anti-VEGF for Diabetic Macular Edema Prior to Cataract Surgery
NCT03832179Phase 4Completed
- Sponsor
- Bay Area Retina Associates
- Start
- Nov 2018
- Primary completion
- Sep 2023
- Modality
- Implantable Devices, Implantable Hydrogels, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ozurdex in diabetic macular edema (DME) (2 arms), sponsored by Bay Area Retina Associates. Primary endpoint: Central Foveal Thickness at 3 months. Started Nov 2018; status: completed.
02
Drugs
ozurdex
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT03832179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03832179.